4 December 2015Americas

Valeant sues Allergan over Relistor ANDA filing

Valeant Pharmaceuticals has slammed Allergan’s attempt to market a generic version of its Relistor (methylnaltrexone bromide) drug.

Valeant filed a patent infringement lawsuit against Allergan at the US District Court for the District of New Jersey, alleging that four of its registered US patents had been infringed by the application to market a generic version.

Relistor is used to treat opioid-induced constipation.

Allergan notified Valeant in October of an Abbreviated New Drug Application filed with the US Food and Drug Administration that sought approval to market a generic version of the drug.

But in its complaint Valeant has complained that the ANDA infringes its patent and has asked the court to deem it “exceptional” and has requested that its legal costs be reimbursed.

The lawsuit was filed on November 30.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk